Immuneering Corporation (Nasdaq: IMRX) priced its public offering of 18,959,914 shares of Class A common stock at $9.23 per share, totaling approximately $175 million. Sanofi will purchase 2,708,559 shares in a private placement. The proceeds will fund product development and general corporate purposes. Leerink Partners and Oppenheimer & Co. are handling the offerings. The public offering is under a shelf registration statement filed with the SEC. The private placement shares have not been registered under the Securities Act of 1933. Forward-looking statements caution investors of risks associated with economic conditions. Contact Carson Creehan at [email protected] for media inquiries or Laurence Watts at [email protected] for investor relations. Visit the SEC website for more information on the offerings.

Read more at GlobeNewswire: Immuneering Announces Pricing of $175 Million Underwritten